2023 pharma predictions
The pandemic continued to affect supply chains, inflation was at a recent all-time high, and FDA approvals hit a five-year low. The Inflation Reduction Act was signed into law back in August, promising to limit the pharma industry’s pricing power.
Despite these tests, the industry experienced pivotal moments. Humira’s patent expiration led to CDER’s 40th biosimilar approval — with more to follow. There was a surge of gene therapy approvals, including the first gene therapy for hemophilia B.
- Read more about 2023 pharma predictions
- Log in to post comments
Looking into the OSD Crystal Ball: Industry Experts Reflect on Opportunities & Challenges in '23 & Beyond
The Future of Quality in Manufacturing
The next decade will see pharmaceutical companies change their manufacturing ecosystems with emphasis on product quality, speed to market, efficiency, waste reduction, cost containment and skill retention to meet regulatory and consumer demands. To achieve this, companies are embarking on a digital transformation journey towards a new manufacturing strategy, a concept called Pharma 4.0., to achieve their competitive advantage.
2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain.
Considerations for Manufacturing Solid Versus Semi-solid Drugs
Manufacturers must consider key components of manufacturing solid versus semi-solid drugs to create a successful end product.
What is pelletisation, and how is it advancing nutraceuticals and dietary supplements?
Pelletization has attracted much attention across the nutraceutical sector. Experts from ACG explain why.
Nutraceuticals are gaining popularity as an effective tool for maintaining health as public awareness of the advantages of health supplements grows. According to market analysis, the global nutraceutical segment is anticipated to increase in value from $450 billion in 2021 to $746 billion by 2028, with a projected compound annual growth rate (CAGR) of around 8.8%.1
Top pharma industry trends to watch for in 2023
EPM conducted a roundtable with several pharma experts to learn what industry trends to watch out for in 2023, from AI drug discovery through to the rise of decentralised trials.